Publications

Bradley E. Chipps, MD

93. Luskin, AT, Chipps BE, Rasouliyan, L, Miller, DP, Haselkorn, T, and Dorenbaum, A. Impact of asthma exacerbations and asthma triggers on asthma-related quality-of-life in patients with severe or difficult-to-treat asthma. The Journal of Allergy and Clinical Immunology: In Practice 2014 (In Press).

92. Chipps, BE, Anderson, CT, and Harder, J. Fractional exhaled nitric oxide of at least 100 and implications for future asthma research. Ann Allergy Asthma Immunol 2014;113:118-19.

91. Tashkin DO, Chipps BE, Trudo F, Zangrilli JG: Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect. J Asthma 2014 Feb 14. doi:10.3109/02770903.2014.895012 (Epub ahead of print)

90. Cleveland, C., Stewart, L., Chipps, B.E., and Spahn J.D. Diagnosis of Asthma in Preschool-Age Children. Clinical Asthma: Theory and Practice 2014. Chapter 6;57-64.

89. Schatz, M., Zeiger, R., Chipps, B., Dorenbaum, A., Chen, W., Hsu, J. Miller, D. and Mink, D. Phenotypes Determined by Cluster Analysis in Severe or Difficult-to-treat Asthma. J Allergy Clin Immunol 2013;133(6):1549-1556.

88. Kharrazi, M., Prach, L., Chipps, B., et al. Novel CFTR Variants Identified During the First Three Years of Cystic Fibrosis Newborn Screening in California. The Journal of Molecular Diagnostics 2013.

87. Chipps, B., and Mellon, M. Asthma. Encyclopedia of Inflammatory Diseases 2013 .

86. Chipps, B. Update in Pediatric Anaphylaxis: A Systemic Review. Clinical Pediatrics 2013;52(5):447-57.

85. Chipps, B., Zeiger, R., Dorenbaum, A., Borish, L., Wenzel, S., Miller, D., Hayden, M., Bleecker, E., Simons, E., Szefler, S., Weiss, S., Haselkorn, T., and TENOR Study Group. Assessment of asthma control and asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) observational cohort. Current Respiratory Care Reports 2012;1:259–269.

84. Chipps, B., Figliomeni, M., and Spector, S. Omalizumab: An Update on Efficacy and Safety in Moderate-to-Severe Allergic Asthma. Allergy and Asthma Proceedings 2012;33:377-85.

83. Chipps, B., Zeiger, R., Borish, L., Wenzel, S., Yegin, A., Hayden, M., Miller, D., Bleecker, E., Simons, E., Szefler, S., Weiss, S., and Haselkorn, T. Key Findings and Clinical Implications from the Epidemiology and Natural History of Asthma: Outcomes and T reatment Regiments (TENOR) Study. J Allergy Clin Immunol. 2012;130:332-42.

82. Zeiger, R., Yegin, A., Simons, E.R., Haselkorn, T., Rasouliyan, L., Szefler, S., Chipps, B.E., and the TENOR study group. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol. 2012;108:81-87.

***Updated 7/6/2020***

FROM CAPITAL ALLERGY & RESPIRATORY DISEASE CENTER
Due to current recommendations made by the US Government/CDC – The Following will go into effect until further notice.

Within the health care community as a whole, there has been an overall increase in the number of patients not seeking necessary medical treatment due to concerns about COVID-19.

If you have a medical problem, please contact your health care provider. It’s important not to delay seeking treatment when you need it.

We are currently open for in-office visits and will continue to offer telemedicine visits moving forward. We understand you might have concerns about coming in to see your health care provider. We want you to know about the steps we are taking to ensure your safety and help prevent the spread of infection:

o Mandatory Masking – All patients and visitors must be masked while in any of our care sites. Please wear a mask or face covering when you enter our facility.

o Limiting Individuals at Appointments – We will limit who is present at a patient visit. Only the patient will be allowed into the facility. If the patient is a minor, only one parent/guardian will be allowed to accompany the patient.

o Temperature Checks – All patients (and parent/guardian if patient is a minor) will have their temperatures checked at the door. Anyone with a temperature of 100 degrees or higher will be asked to reschedule their appointment or conduct the appointment via telemedicine.

o Employee Screening – We’ve instituted mandatory employee temperature screenings before each shift.

New Injection Hours – Effective 7/6/2020

Folsom Office
Monday 8:00-11:45 / 1-4:45
Tuesday Closed
Wednesday 8:00-11:45 / 1-4:45
Thursday 8:00-11:45 / 1-4:45
Friday 8:00-11:45 / 1-4:45

Roseville Office
Monday 9:00-11:45 / 1-4:45
Tuesday 8:00-11:45 / 1-4:45
Wednesday 8:00-11:45 / 1-4:45
Thursday 8:00-11:45 / 1-4:45
Friday 8:00-11:45 / 1-4:45

Sacramento
Monday 9:00-4:45
Tuesday 8:00-5:45
Wednesday 8:00-4:45
Thursday 9:00-4:45
Friday 8:00-4:45